Marker Therapeutics
MRKR
56 hedge funds and large institutions have $101M invested in Marker Therapeutics in 2019 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 7 closing their positions.
186% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 7
117% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 6
30% more funds holding
Funds holding: 43 → 56 (+13)
17% more capital invested
Capital invested by funds: $86.4M → $101M (+$14.5M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.07% less ownership
Funds ownership: 3.43% → 3.36% (-0.07%)
39% less call options, than puts
Call options by funds: $69K | Put options by funds: $114K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.58M |
| 2 |
Millennium Management
New York
|
+$1.04M |
| 3 |
BlackRock
New York
|
+$767K |
| 4 |
LCM
Laurion Capital Management
New York
|
+$569K |
| 5 |
MA
MYDA Advisors
Woodmere,
New York
|
+$484K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$8.26M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$281K |
| 3 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$208K |
| 4 |
Barclays
London,
United Kingdom
|
-$172K |
| 5 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$64K |
MRKR Hedge Fund Activity: Q1 2019 in Review
56 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q1 2019, worth a combined $101M — up 17% from $86.4M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new MRKR positions and 7 closed out — a net gain of 13 holders — while 13 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.58M. The largest seller was Armistice Capital, exiting entirely with an estimated $8.26M sold.
- 56 institutional investors held Marker Therapeutics (MRKR) as of Q1 2019, up from 43 in Q4 2018.
- Funds reported $101M of Marker Therapeutics stock for Q1 2019, up 17% quarter-over-quarter.
- 20 funds opened new Marker Therapeutics positions in Q1 2019 and 7 closed out, a net change of +13 holders.
- The largest Marker Therapeutics buyer in Q1 2019 was Vanguard Group, an estimated $1.58M added.
- The largest Marker Therapeutics seller in Q1 2019 was Armistice Capital, an estimated $8.26M sold.
Based on aggregated 13F filings for Q1 2019.